Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 2Recurrence 1Prostatic Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Fulvestrant 2serabelisib 1sapanisertib 1ribociclib 1palbociclib 1olaparib 1niraparib 1inavolisib 1exemestane 1capivasertib 1abemaciclib 1Tamoxifen 1STX-478 1Paclitaxel 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1CYH33 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × CYH33 × Gynecologic × Clear all
NCT04586335 2024-03-21

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Haihe Biopharma Co., Ltd.

Phase 1 Terminated
24 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡